Premium
Refractory pyoderma gangrenosum treated with infliximab in an infant
Author(s) -
CamposMuñoz L.,
CondeTaboada A.,
Aleo E.,
Toledano E.,
LópezBran E.
Publication year - 2014
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.12297
Subject(s) - medicine , pyoderma gangrenosum , infliximab , dermatology , disease
Summary We report the case of an 11‐month‐old boy with severe recalcitrant pyoderma gangrenosum refractory to prednisone, dapsone and ciclosporin. Treatment with infliximab was well tolerated, and resulted in an excellent clinical response that has been sustained for 15 months. The characteristics of this condition in children and the use of infliximab in infants are both reviewed.